Stay updated on Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial
Sign up to get notified when there's something new on the Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial page.

Latest updates to the Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedRevision tag updated from v3.5.3 to v3.5.4 on the page. This indicates a minor internal update to the entry without altering study details or displayed information.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedRevision updated from v3.5.2 to v3.5.3, indicating a minor update to the page's revision history for this study record on ClinicalTrials.gov.SummaryDifference0.1%

- Check41 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check69 days agoChange DetectedRevision metadata updated: added v3.5.0 and removed v3.4.3.SummaryDifference0.1%

- Check76 days agoChange DetectedThe page now shows Revision: v3.4.3, replacing the prior v3.4.2.SummaryDifference0.1%

- Check105 days agoChange DetectedRevision: v3.4.2 added. The previous notice about a lapse in government funding and related operating status information (Revision: v3.4.1) was removed.SummaryDifference0.4%

Stay in the know with updates to Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial page.